SCHEMBL4018201

SCHEMBL4018201

Cc1[se]c(/C=C2\C(=O)Nc3ccc(F)cc32)cc1C(=O)NCCN1CCOCC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.69
PDGFRB P09619 7/20 0.69
FGFR1 P11362 3/20 0.69
CHEK1 O14757 7/20 0.66
TLK2 Q86UE8 3/20 0.59
KIT P10721 5/20 0.56
FLT3 P36888 3/20 0.55
RIOK2 Q9BVS4 2/20 0.55
TLK1 Q9UKI8 2/20 0.55
FLT1 P17948 2/20 0.55
BMPR1B O00238 1/20 0.55
PLK4 O00444 1/20 0.55
STK25 O00506 1/20 0.55
CIT O14578 1/20 0.55
RIOK3 O14730 1/20 0.55
IKBKB O14920 1/20 0.55
GAK O14976 1/20 0.55
DCLK1 O15075 1/20 0.55
CHUK O15111 1/20 0.55
MUSK O15146 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4018205 1.00 KDR (0.69) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4174939 0.93 CHEK1 (0.70) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4174935 0.93 CHEK1 (0.70) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4166006 0.86 CHEK1 (0.78) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4165999 0.86 CHEK1 (0.78) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4017088 0.85 CHEK1 (0.55) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4017090 0.85 CHEK1 (0.55) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL5830182 0.82 PDGFRB (1.00) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL5830179 0.82 PDGFRB (1.00) KDRPDGFRBFGFR1CHEK1TLK2
SCHEMBL4013804 0.81 CHEK1 (0.70) KDRPDGFRBFGFR1CHEK1TLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009085040-A1 PROTEIN KINASE INHIBITORS DCB-USA LLC (US) 2009-07-09 WO disclosed
US-20090163494-A1 PROTEIN KINASE INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163494-A1 PROTEIN KINASE INHIBITORS BRAF, MAP3K20, SELENOI KDR 2756/4885PDGFRB 2877/4885FGFR1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.